Telogen Effluvium in Patients Recovering from COVID-19

Nancy Wei, Emily Elbogen, Joshua Dan, Anna Chessky, Ryan Rivera-Oyola, Mark Lebwohl

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: We characterized and summarized clinical and demographic features in patients with post-COVID 19 Telogen Effluvium and compared it with those reported in the literature. Methods: We collected data from 10 participants and measured average onset of TE from initial COVID-19 symptoms, medical intervention for COVID-19 infection, physical exam findings, and whether or not patient experienced resolution of TE symptoms after 14 weeks. We performed a literature review using the terms “telogen effluvium”, “covid” and “hair” and investigation was limited to adult case reports and cohort studies appearing in the English-Language literature as of March 2021. Clinical and demographic findings were analyzed and compared with those of our patient cohort. Results: Nine out of ten patients in our cohort had mild COVID-19 symptoms only with mean onset of hair shedding was 73 days following infection. None had previous history of hair loss. By contrast, of the 28 patients identified in the literature review 50% of these patients were hospitalized for severe COVID-19 infection with average onset of TE 87 day after infection. 12% of these patients had pre-existing androgenic alopecia. Conclusion: Telogen Effluvium is a distressing, yet self-limited condition that can occur following both mild and severe COVID-19 infection. Dermatologists should expect an increase in TE in areas heavily affected by COVID-19 and reassure patients of the likely cause and that symptoms will resolve over time.

Original languageEnglish
Pages (from-to)533-537
Number of pages5
JournalSKIN: Journal of Cutaneous Medicine
Volume5
Issue number5
DOIs
StatePublished - 13 Sep 2021

Keywords

  • COVID-19
  • Telogen effluvium
  • general dermatology
  • hair loss
  • medical dermatology

Fingerprint

Dive into the research topics of 'Telogen Effluvium in Patients Recovering from COVID-19'. Together they form a unique fingerprint.

Cite this